Long-term Observational Study of the Safety of Roflumilast
Long-Term Post-Marketing Observational Study of the Safety of Roflumilast
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bremen, Germany
- Research Site
-
-
-
-
-
Oslo, Norway, 0483
- Research Site
-
-
-
-
-
Solna, Sweden
- Research Site
-
-
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02139
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Exposed Cohort selection
Inclusion Criteria:
- Have one or more prescription(s) of roflumilast with the date of first prescription/dispensation defined as the Cohort Entry Date
- Have active data in the respective database(s) for at least 1 year prior to the Cohort Entry Date
- Be at least 40 years old at Cohort Entry Date
- Have a diagnosis of COPD or chronic bronchitis prior to the Cohort Entry Date (databases with outpatient diagnoses) or (databases without outpatient diagnoses) either a hospital diagnosis of COPD or chronic bronchitis prior to the Cohort Entry Date or a proxy for such indication based on prescription data.
Non-Exposed Cohort selection Patients meeting the following inclusion criteria belong in the Non-Exposed Cohort and are eligible as Matched Non-Exposed controls. Each patient in the Non-exposed Cohort selected as matched exposed patient is assigned as a Cohort Entry Date the date of the first roflumilast prescription of the matched exposed patient.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Roflumilast exposed
Patients with COPD ever exposed to Roflumilast
|
Roflumilast
|
|
Roflumilast unexposed
Patients with COPD never exposed to Roflumilast
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause mortality
Time Frame: up to 5 years
|
Safety objective to estimate 5-year all-cause mortality
|
up to 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
death by suicide or hospitalization for suicide attempt
Time Frame: up to 5 years
|
Secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
hospitalization for any cause
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
Major cardiovascular events
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
Respiratory disease related hospitalization
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
New diagnoses of depression
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
New diagnoses of malignant neoplasm
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
Hospitalization due to serious diarrhea of non-infectious origin
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
Abnormal and unexplained weight loss
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
New diagnosis of tuberculosis or hepatitis B or C
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
|
Other severe viral hepatitis infection (except hepatitis A)
Time Frame: up to 5 years
|
secondary safety issue (occurring up to 5 years)
|
up to 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Edeltraut Garbe, Dr. med., Leibniz Inst for Prevention & Epidemiology - BIPS GmbH
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- D7120R00003
- EUPAS14852 (Registry Identifier: ENCePP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.